Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06865482 · ClinicalTrials.gov registry record
Clinical Course Of Disease In Participants With FA-CM
A clinical trial of Cardiomyopathy and Friedreich Ataxia, sponsored by Lexeo Therapeutics.
- Recruiting
- Registry status
- 65
- Enrollment target
- 10
- Study locations
NCT06865482 is a study of Cardiomyopathy and Friedreich Ataxia that is actively recruiting participants, run by Lexeo Therapeutics. The registered enrollment target is 65 participants, below the 554-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT06865482, a study of Cardiomyopathy and Friedreich Ataxia, is actively recruiting participants, sponsored by Lexeo Therapeutics.
- RECRUITING
- Registry status
- 65 participants
- Enrollment target
- 10
- Study locations
Study Summary
Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)
Conditions Studied
Study Locations (10)
Other
- Motol University Hospital and the Second Faculty of Medicine - Prague
- Institut de Cardiologie Hopital Pitie Salpetriere - Paris
California
- University of California San Diego - La Jolla
Florida
- University of South Florida - Tampa
Indiana
- Indiana University - Riley Children's Health - Indianapolis
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Ohio
- Cincinnati Children's Hospital - Cincinnati
Quebec
- Centre Hospitalier de Universite de Montreal (CHUM) - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2027-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06865482
The ClinicalTrials.gov registry entry for NCT06865482 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 554-participant average among 25 other Cardiomyopathy trials with a reported enrollment target (88% lower). The listed sponsor is Lexeo Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT06865482 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06865482 about?
NCT06865482 is a clinical study titled "Clinical Course Of Disease In Participants With FA-CM". Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)
What is the current status of trial NCT06865482?
This trial is currently recruiting. The enrollment target is 65 participants. The study started on 2025-09-30. Estimated completion is 2027-09.
What conditions does trial NCT06865482 study?
This clinical trial studies the following conditions: Cardiomyopathy, Friedreich Ataxia.
Who is sponsoring clinical trial NCT06865482?
This trial is sponsored by Lexeo Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06865482 being conducted?
This trial has 10 study locations across California, Florida, Indiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
RECRUITING · Phase 4
-
Molecular Imaging of Primary Amyloid Cardiomyopathy
RECRUITING · NA
-
Impella Reverse Remodeling in End-Stage Heart Failure
RECRUITING
-
Genetics of Cardiovascular and Neuromuscular Disease
RECRUITING
-
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.